Show simple item record

dc.contributor.authorVaidyanathan, D.
dc.contributor.authorWilliams, A.
dc.contributor.authorDordick, J.S.
dc.contributor.authorKoffas, M.A.G.
dc.contributor.authorLinhardt, Robert J.
dc.date2016
dc.date.accessioned2022-06-23T04:28:44Z
dc.date.available2022-06-23T04:28:44Z
dc.date.issued2016
dc.identifier.citationEngineered heparins as new anticoagulant drugs, D. Vaidyanathan, A. Williams, J. S. Dordick, M. A.G. Koffas, Robert J. Linhardt, Bioengineering & Translational Medicine, 2, 17–30, 2016.
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5385
dc.identifier.urihttps://doi.org/10.1002/btm2.10042
dc.descriptionBioengineering & Translational Medicine, 2, 17–30
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractHeparin is an anionic polysaccharide that is widely used as a clinical anticoagulant. This glycosaminoglycan is prepared from animal tissues in metric ton quantities. Animal-sourced heparin is also widely used in the preparation of low molecular weight heparins that are gaining in popularity as a result of their improved pharmacological properties. The recent contamination of pharmaceutical heparin together with concerns about increasing demand for this life saving drug and the fragility of the heparin supply chain has led the scientific community to consider other potential sources for heparin. This review examines progress toward the preparation of engineered heparins through chemical synthesis, chemoenzymatic synthesis, and metabolic engineering.
dc.languageen_US
dc.language.isoENG
dc.publisherWiley
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleEngineered heparins as new anticoagulant drugs
dc.typeArticle
dcterms.accessRightsA full text version is available in DSpace@RPI
dcterms.isVersionOfhttps://doi.org/10.1002/btm2.10042
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record